Avoid concomitant intake of grapefruit or grapefruit juice due to increased finerenone exposure.
Source: NLP:finerenone
Brand names: Kerendia
Nonsteroidal Mineralocorticoid-Receptor Antagonist · Mineralocorticoid Receptor Antagonists
Route: Oral
Contraindications
4 CONTRAINDICATIONS Kerendia is contraindicated in patients: Who are hypersensitive to any component of this product [see Adverse Reactions (6.2) ] . Who are receiving concomitant treatment with strong CYP3A4 inhibitors [see Drug Interactions (7.1) ]. With adrenal insufficiency. Concomitant use with strong CYP3A4 inhibitors. ( 4 , 7.1 ) Patients with adrenal insufficiency. ( 4 ) Hypersensitivity to any component of this product. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data on Kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies have shown developmental toxicity at exposures about 2 times those expected in humans (see Data ) . The clinical significance of these findings is unclear. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In the embryo-fetal toxicity study in rats, finerenone resulted in reduced placental weights and signs of fetal toxicity, including reduced fetal weights and retarded ossification at the maternal toxic dose of 10 mg/kg/day corresponding to an AUC unbound of at least 7 times that in humans. At 30 mg/kg/day, the incidence of visceral and skeletal variations was increased (slight edema, shortened umbilical cord, slightly enlarged fontanelle) and one fetus showed complex malformations including a rare malformation (double aortic arch) at an AUC unbound of about 10 times that in humans at the 40 mg dose and about 25 times that in humans at the 20 mg dose. The doses free of any findings (low dose in rats, high dose in rabbits) provide safety margins of 4 to 5 times for the AUC unbound expected in humans. When rats were exposed during pregnancy and lactation in the pre- and postnatal developmental toxicity study, increased pup mortality and other adverse effects (lower pup weight, delayed pinna unfolding) were observed at about 2 or 4 times the AUC unbound expected in humans at the dose of 40 mg and 20 mg, respectively. In addition, the offspring showed slightly increased locomotor activity, but no other neurobehavioral chan
8 interactions on record
Avoid concomitant intake of grapefruit or grapefruit juice due to increased finerenone exposure.
Source: NLP:finerenone
Avoid concomitant intake of grapefruit as it acts as a strong CYP3A4 inhibitor.
Source: NLP:finerenone
Co-administration is contraindicated; itraconazole increases plasma concentrations, potentially increasing pharmacologic effects and adverse reactions.
Source: NLP:itraconazole
Concomitant use with strong CYP3A4 inhibitors increases finerenone exposure and may increase risk of adverse reactions.
Source: NLP:finerenone
Avoid concomitant use as it decreases finerenone exposure and may reduce efficacy of finerenone.
Source: NLP:finerenone
Decreases finerenone exposure which may reduce efficacy of finerenone; avoid concomitant use.
Source: NLP:finerenone
More frequent serum potassium monitoring is warranted with concomitant use due to increased risk of hyperkalemia.
Source: NLP:finerenone
Finerenone 40 mg is a weak CYP2C8 inhibitor and increases exposure of CYP2C8 substrates; monitor patients more frequently for adverse reactions.
Source: NLP:finerenone